Detalhe da pesquisa
1.
Development and Validation of SCACOMS, a Composite Scale for Assessing Disease Progression and Treatment Effects in Spinocerebellar Ataxia.
Cerebellum
; 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38710966
2.
Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
Ann Hematol
; 103(1): 5-15, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37804344
3.
Application of text mining to the development and validation of a geographic search filter to facilitate evidence retrieval in Ovid MEDLINE: An example from the United States.
Health Info Libr J
; 40(2): 169-180, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36541200
4.
Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant - post hoc results from an open label safety study (BHV3000-201).
J Headache Pain
; 23(1): 10, 2022 Jan 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35038983
5.
Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
Headache
; 61(6): 906-915, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34021585
6.
Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma.
Future Oncol
; 17(5): 611-627, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33052055
7.
Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma.
Value Health
; 23(4): 441-450, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32327161
8.
Observing the Clinical Course of Duchenne Muscular Dystrophy in Medicaid Real-World Healthcare Data.
Adv Ther
; 41(6): 2519-2530, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38698169
9.
Toenail Onychomycosis with or without Diabetes in Canada: Patient Treatment Preferences and Health State Utilities.
Patient Prefer Adherence
; 18: 475-486, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38410773
10.
Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK.
J Med Econ
; 27(1): 627-643, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38590236
11.
Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305).
Adv Ther
; 40(2): 585-600, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36417057
12.
Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis.
Lung Cancer
; 177: 11-20, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36669321
13.
Characterizing the Occurrence of Key Clinical Milestones in Duchenne Muscular Dystrophy in the United States Using Real-World Data.
J Neuromuscul Dis
; 9(6): 689-699, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36245384
14.
Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm.
Clin J Pain
; 38(11): 680-685, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36125279
15.
Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome.
J Med Econ
; 25(1): 249-259, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35020547
16.
Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis.
Expert Rev Pharmacoecon Outcomes Res
; 22(1): 155-166, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34148501
17.
Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis.
Lung Cancer
; 170: 122-132, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35767923
18.
Characterizing demographics, comorbidities, and costs of care among populations with Duchenne muscular dystrophy with Medicaid and commercial coverage.
J Manag Care Spec Pharm
; 27(10): 1426-1437, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34595954
19.
Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant.
Adv Ther
; 38(10): 5209-5220, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34455556
20.
A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome.
J Med Econ
; 23(12): 1503-1515, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33001704